Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID D WRIGHT

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1699745638
CMS profile
167264
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$4,318.15

222 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,312.73 221
Education $5.42 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $372.65 26
Janssen Biotech, Inc. $313.96 21
Seagen Inc. $282.62 11
Gilead Sciences, Inc. $272.68 13
Lilly USA, LLC $255.18 11
Celgene Corporation $248.46 12
Merck Sharp & Dohme LLC $247.13 12
Daiichi Sankyo Inc. $182.01 7
PFIZER INC. $175.99 11
Eisai Inc. $174.67 8
Incyte Corporation $152.85 9
E.R. Squibb & Sons, L.L.C. $131.12 8
Pharmacyclics LLC, An AbbVie Company $130.96 5
Dendreon Pharmaceuticals LLC $96.22 3
Regeneron Healthcare Solutions, Inc. $95.69 4
Mirati Therapeutics, Inc. $86.75 4
Astellas Pharma US Inc $83.05 4
Kite Pharma, Inc. $80.17 4
BeiGene USA, Inc. $72.56 3
Amgen Inc. $67.91 4
Exelixis Inc. $57.17 3
Puma Biotechnology, Inc. $48.26 2
Sumitomo Pharma America, Inc. $47.27 3
Bayer Healthcare Pharmaceuticals Inc. $45.51 2
CTI BioPharma Corp. $44.69 3
GlaxoSmithKline, LLC. $41.81 2
Stemline Therapeutics Inc. $40.01 2
AVEO Pharmaceuticals, Inc. $36.98 2
TerSera Therapeutics LLC $34.00 1
Karyopharm Therapeutics Inc. $33.19 2
GENZYME CORPORATION $32.78 1
Genentech USA, Inc. $32.39 2
Blueprint Medicines Corporation $32.03 2
Telix Pharmaceuticals $24.57 1
SERVIER PHARMACEUTICALS LLC $24.56 1
Genmab U.S., Inc. $24.30 1
TAIHO ONCOLOGY, INC. $20.34 1
Apellis Pharmaceuticals, Inc. $19.96 1
ARRAY BIOPHARMA INC $18.99 1
Agios Pharmaceuticals, Inc. $18.26 1
ADC Therapeutics America, Inc. $17.84 1
Deciphera Pharmaceuticals Inc. $17.43 1
SOBI, INC $17.28 1
MorphoSys, US Inc. $16.04 1
AbbVie Inc. $15.30 1
Pharmacosmos Therapeutics Inc. $14.62 1
Foundation Medicine, Inc. $14.52 1
Rigel Pharmaceuticals, Inc. $5.42 1

Page 3 of 5; records 101–150 of 222 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID D WRIGHT

NPI 1699745638 · CMS profile ID 167264

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 222 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699745638?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID D WRIGHT, NPI 1699745638, CMS profile ID 167264. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 222 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699745638?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DAVID D WRIGHT, NPI 1699745638, CMS profile ID 167264. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 222 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699745638?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DAVID D WRIGHT, NPI 1699745638, CMS profile ID 167264, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 222 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1699745638?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

222 matching records · $4,318.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 222 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 222.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $27.5007/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988276917 CMS
Astellas Pharma US Inc $15.8507/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034278503 CMS
BeiGene USA, Inc. $22.5707/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051195337 CMS
Sumitomo Pharma America, Inc. $12.8107/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030716801 CMS
Regeneron Healthcare Solutions, Inc. $17.9307/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999550035 CMS
Regeneron Healthcare Solutions, Inc. $23.2407/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999550023 CMS
AVEO Pharmaceuticals, Inc. $18.3907/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049057805 CMS
Incyte Corporation $7.7007/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044503829 CMS
Incyte Corporation $3.8007/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044503819 CMS
Dendreon Pharmaceuticals LLC $33.6206/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060292561 CMS
Novartis Pharmaceuticals Corporation $11.7706/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993414717 CMS
ARRAY BIOPHARMA INC $18.9906/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049456407 CMS
Gilead Sciences, Inc. $22.4006/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025729033 CMS
Seagen Inc. $7.6706/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995690067 CMS
Pharmacyclics LLC, An AbbVie Company $25.9706/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297977 CMS
Novartis Pharmaceuticals Corporation $10.0306/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993414713 CMS
Novartis Pharmaceuticals Corporation $5.6606/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993414715 CMS
Pharmacyclics LLC, An AbbVie Company $27.9306/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297975 CMS
CTI BioPharma Corp. $16.7306/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039689415 CMS
Lilly USA, LLC $21.7106/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031330039 CMS
Celgene Corporation $34.7106/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014980741 CMS
Exelixis Inc. $21.5906/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044567891 CMS
Novartis Pharmaceuticals Corporation $16.7806/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993414701 CMS
Novartis Pharmaceuticals Corporation $10.1906/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993414703 CMS
PFIZER INC. $18.3606/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050496573 CMS
Exelixis Inc. $21.2706/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044565695 CMS
Janssen Biotech, Inc. $19.9106/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988276957 CMS
Janssen Biotech, Inc. $0.7006/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988276967 CMS
Janssen Biotech, Inc. $1.6606/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988276977 CMS
Seagen Inc. $20.9106/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995690081 CMS
Gilead Sciences, Inc. $12.2705/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026055799 CMS
TerSera Therapeutics LLC $34.0005/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052415299 CMS
Gilead Sciences, Inc. $22.6405/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025720475 CMS
Merck Sharp & Dohme LLC $17.6105/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048829913 CMS
PFIZER INC. $7.9105/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050680515 CMS
Puma Biotechnology, Inc. $25.6805/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059061573 CMS
Merck Sharp & Dohme LLC $25.1505/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048577695 CMS
Merck Sharp & Dohme LLC $19.9605/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048577521 CMS
Merck Sharp & Dohme LLC $12.8705/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048577519 CMS
Mirati Therapeutics, Inc. $22.5005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058006557 CMS
Dendreon Pharmaceuticals LLC $26.5905/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060292559 CMS
Janssen Biotech, Inc. $1.4905/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988276987 CMS
Janssen Biotech, Inc. $3.4005/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988276997 CMS
Janssen Biotech, Inc. $25.1605/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988277007 CMS
Janssen Biotech, Inc. $3.2805/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988277017 CMS
Celgene Corporation $15.5805/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014980715 CMS
Lilly USA, LLC $59.3505/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031368001 CMS
Astellas Pharma US Inc $16.3605/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034101523 CMS
Stemline Therapeutics Inc. $18.0405/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040023923 CMS
Janssen Biotech, Inc. $26.8805/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988277027 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $18,426.87 202
PY2020 $1,295.81 74
PY2021 $4,473.01 68
PY2022 $9,484.08 145
PY2023 $4,318.15 222
PY2024 $4,692.11 220
PY2025 $4,795.40 198

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,446.88 2
PY2025 Principal investigator $787,277.12 47
PY2024 Principal investigator $547,309.75 19
PY2023 Principal investigator $203,022.34 15
PY2022 Principal investigator $391,313.17 29
PY2021 Principal investigator $584,725.22 39
PY2020 Principal investigator $429,379.09 39
PY2019 Principal investigator $359,070.75 142

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,792.09 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185551062
Principal investigator 1 Genentech, Inc. $54.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211652747
Recipient F. Hoffmann-La Roche AG $862.55 12/10/2025 Covered Recipient Physician A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211535307
Recipient F. Hoffmann-La Roche AG $584.33 12/08/2025 Covered Recipient Physician A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211535303
Principal investigator 1 AstraZeneca UK Limited $500.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185551074
Principal investigator 1 PFIZER INC. $1,250.00 11/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228724800
Principal investigator 1 Genentech, Inc. $688.00 11/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652577
Principal investigator 1 AstraZeneca Pharmaceuticals LP $937.73 11/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
DESTINY-Breast07 will investigate the safety tolerability and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer No dispute reported 06/30/2026 1185551072
Principal investigator 1 PFIZER INC. $1,250.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228720459
Principal investigator 1 PFIZER INC. $1,250.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228728689
Principal investigator 1 PFIZER INC. $1,250.00 11/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228729263
Principal investigator 1 Genentech, Inc. $15,158.00 10/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652504
Principal investigator 1 ABBVIE INC. $6,143.88 09/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202510378
Principal investigator 1 ABBVIE INC. $240.62 09/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202510288
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,691.00 08/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
DESTINY-Breast07 will investigate the safety tolerability and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer No dispute reported 06/30/2026 1185551064
Principal investigator 1 Genentech, Inc. $688.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651972
Principal investigator 1 Genentech, Inc. $12,028.00 07/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652170
Principal investigator 1 ABBVIE INC. $510.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202499382
Principal investigator 1 Genentech, Inc. $6,014.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652095
Principal investigator 1 Genentech, Inc. $63.75 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652260
Principal investigator 1 Genentech, Inc. $95.00 07/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211652278
Principal investigator 1 Genentech, Inc. $688.00 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651891
Principal investigator 1 Genentech, Inc. $15,408.00 07/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651869
Principal investigator 1 Genentech, Inc. $155.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650962
Principal investigator 1 Genentech, Inc. $40.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651236
Principal investigator 1 Genentech, Inc. $313.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651288
Principal investigator 1 Genentech, Inc. $125.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651396
Principal investigator 1 Genentech, Inc. $375.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651416
Principal investigator 1 Genentech, Inc. $66.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651420
Principal investigator 1 Genentech, Inc. $40.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651474
Principal investigator 1 Genentech, Inc. $155.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651575
Principal investigator 1 AstraZeneca UK Limited $188,630.67 06/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185551066
Principal investigator 1 ABBVIE INC. $510.00 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202485677
Principal investigator 1 AstraZeneca Pharmaceuticals LP $245,246.20 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185551068
Principal investigator 1 AstraZeneca Pharmaceuticals LP $250.92 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185551076
Principal investigator 1 Genentech, Inc. $15,000.00 04/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211650907
Principal investigator 1 Genentech, Inc. $5,441.00 04/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651370
Principal investigator 1 ABBVIE INC. $125.00 04/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202474499
Principal investigator 1 ABBVIE INC. $510.00 04/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202474503
Principal investigator 1 Genentech, Inc. $63.75 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651006
Principal investigator 1 Genentech, Inc. $40.00 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651112
Principal investigator 1 Genentech, Inc. $95.00 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651279
Principal investigator 1 Genentech, Inc. $66.00 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651309
Principal investigator 1 Genentech, Inc. $125.00 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651315
Principal investigator 1 Genentech, Inc. $40.00 04/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211651500
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,900.00 01/24/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Nave Subjec No dispute reported 06/30/2026 1235993793
Principal investigator 1 AstraZeneca UK Limited $218,256.00 01/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185551060
Principal investigator 1 ABBVIE INC. $534.38 01/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202437902
Principal investigator 1 AstraZeneca UK Limited $2,474.13 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185551070